MXPA01009461A - Tratamiento de osteoartritis. - Google Patents

Tratamiento de osteoartritis.

Info

Publication number
MXPA01009461A
MXPA01009461A MXPA01009461A MXPA01009461A MXPA01009461A MX PA01009461 A MXPA01009461 A MX PA01009461A MX PA01009461 A MXPA01009461 A MX PA01009461A MX PA01009461 A MXPA01009461 A MX PA01009461A MX PA01009461 A MXPA01009461 A MX PA01009461A
Authority
MX
Mexico
Prior art keywords
osteoarthritis
treatment
optinally
gout
monohydrate
Prior art date
Application number
MXPA01009461A
Other languages
English (en)
Inventor
Carl M Mendel
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MXPA01009461A publication Critical patent/MXPA01009461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de la formula (I) o una sal farmaceuticamente aceptable del mismo, en el cual R1 y R2 son independientemente H o metilo (por ejemplo, hidrocloruro de N, N-dimetil-1-[1-4-clorofenil)ciclobutiI]-3-metilbutil amina, opcionalmente en la forma de su monohidrato), se utiliza para tratar osteoartritis o gota.
MXPA01009461A 1999-03-19 2000-03-17 Tratamiento de osteoartritis. MXPA01009461A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12530099P 1999-03-19 1999-03-19
PCT/US2000/007072 WO2000056306A1 (en) 1999-03-19 2000-03-17 Treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
MXPA01009461A true MXPA01009461A (es) 2004-03-19

Family

ID=22419072

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01009461A MXPA01009461A (es) 1999-03-19 2000-03-17 Tratamiento de osteoartritis.

Country Status (20)

Country Link
EP (1) EP1169027A4 (es)
JP (2) JP2002539248A (es)
KR (1) KR20020038567A (es)
CN (1) CN1352552A (es)
AU (1) AU773490B2 (es)
BG (1) BG105999A (es)
BR (1) BR0009081A (es)
CA (1) CA2366660A1 (es)
CZ (1) CZ20013284A3 (es)
HK (1) HK1044702A1 (es)
HU (1) HUP0200494A2 (es)
IL (1) IL145238A0 (es)
MX (1) MXPA01009461A (es)
NO (1) NO20014477L (es)
NZ (1) NZ514016A (es)
PL (1) PL365463A1 (es)
SK (1) SK13342001A3 (es)
TR (1) TR200102699T2 (es)
WO (1) WO2000056306A1 (es)
ZA (1) ZA200107682B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
EP0708639A4 (en) * 1992-06-23 1997-08-20 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATMENT OF DEPRESSION AND OTHER DISEASES USING OPTICALLY PURE SIBUTTRAMINE
AU4542893A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
EP0763016B1 (en) * 1994-06-01 2000-01-26 Axys Pharmaceuticals, Inc. Compositions and methods for treating mast-cell mediated conditions
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .

Also Published As

Publication number Publication date
NO20014477D0 (no) 2001-09-14
CN1352552A (zh) 2002-06-05
EP1169027A1 (en) 2002-01-09
CZ20013284A3 (cs) 2002-10-16
AU3893200A (en) 2000-10-09
HUP0200494A2 (en) 2002-08-28
KR20020038567A (ko) 2002-05-23
NO20014477L (no) 2001-11-01
CA2366660A1 (en) 2000-09-28
ZA200107682B (en) 2003-06-18
SK13342001A3 (sk) 2002-04-04
BR0009081A (pt) 2003-03-05
IL145238A0 (en) 2002-06-30
BG105999A (en) 2002-06-28
JP2012051904A (ja) 2012-03-15
TR200102699T2 (tr) 2002-03-21
AU773490B2 (en) 2004-05-27
NZ514016A (en) 2001-09-28
PL365463A1 (en) 2005-01-10
WO2000056306A1 (en) 2000-09-28
EP1169027A4 (en) 2004-10-20
JP2002539248A (ja) 2002-11-19
HK1044702A1 (zh) 2002-11-01

Similar Documents

Publication Publication Date Title
MXPA01009404A (es) Metodo para tratar trastornos de alimentacion.
IL112515A0 (en) N,n-dimethyl-1-Ú1-(4-chlorophenyl) cyclobutyl¾-3-methylbutylamine in the treatment of non-insulin dependent diabetes mellitus
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
WO2000056315A8 (en) Treatment of pain
ATE411276T1 (de) Kristalle eines hydroxynorephedrinderivats
MXPA01009461A (es) Tratamiento de osteoartritis.
MXPA01009469A (es) Tratamiento para disminuir la adhesividad de las plaquetas.
MXPA01009468A (es) Tratamiento de hipertension pulmonar.
MXPA01009463A (es) Tratamiento de hernia hiatial.
MXPA01009470A (es) Tratamiento de ciertos canceres asociados con el aumento de peso.
MXPA01009462A (es) Tratamiento de calculos biliares.
MXPA01009465A (es) Perdida de peso despues del embarazo.
MXPA02003516A (es) Clorihidrato de n-[3-[[2-(3,4-dimetoxifenil)etil]amino[propil]-4-nitrobenzamida polimorfico.
BG105996A (en) Method of treating eating disorders